Lundbeck hunts for new success drugs in niche diseases

Following a large reorganization of Lundbeck's R&D department, Lundbeck is ready to lift the veil on its future focus areas.
Lundbeck EVP and Head of R&D Johan Luthmann | Photo: PR / Lundbeck
Lundbeck EVP and Head of R&D Johan Luthmann | Photo: PR / Lundbeck
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

The industry has seen it coming for some time, but in its most recent fiscal report, Lundbeck establishes: The Danish pharmaceutical company will be targeting niches in neurology and psychiatry going forward.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading